New drug cocktails aim to tame metastatic breast cancer

NCT ID NCT02057133

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the disease. Participants have either hormone receptor-positive or HER2-positive metastatic breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib (a targeted cancer drug) combined with other drugs like letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, fulvestrant, pertuzumab, loperamide, or ongoing endocrine therapy
What this could lead to: If successful, this could help identify safe and effective drug combinations for treating metastatic breast cancer, potentially improving disease control.
What could go wrong: This is an early-phase (Phase 1b) safety study with a small number of participants. It is not designed to prove effectiveness, and some combinations may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Locations

Columbia University College of Phys & Surgeons

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Highlands Oncology Group - Duplicate 2

Rogers, Arkansas, 72758, United States
Mayo Clinic

Rochester, Minnesota, 55905-0002, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Peggy and Charles Stephenson Oklahoma Cancer Center

Nashville, Tennessee, 37203, United States
Providence Cancer Center Oncology Hematology Care

Portland, Oregon, 97213, United States
South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 78229-3307, United States
Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States
Univ of Pittsburgh Cancer Inst. (UPCI)

Pittsburgh, Pennsylvania, 15213, United States
University of California - San Diego

La Jolla, California, 92037-0845, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232-6307, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.